Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eduardo Cervantes-Alvarez has a total of 135 co-authors. Here are the top co-authors by number of shared publications:

  • Nalu Navarro-Alvarez

    Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, 15 Vasco de Quiroga, Mexico city, 14080, Mexico.

    6 shared publications
  • David Kershenobich

    Department of Gastroenterology, Hepatology and Liver Transplantation Unit, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Mexico City Mexico

    3 shared publications
  • Osvely Méndez-Guerrero

    Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    3 shared publications
  • Yang Wang

    Department of Pathology University of Pittsburgh Pittsburgh PA

    3 shared publications
  • Alexandra Collin de L'HOrtet

    B Department of Pathology , University of Pittsburgh , Pittsburgh , PA , USA

    2 shared publications
  • Christene A. Huang

    Department of Surgery University of Colorado Anschutz Medical Campus Denver Colorado USA

    2 shared publications

Latest Publications

  • Open Access

    Short-Term Mortality is Reduced and Low-Grade Acute-on-Chronic Liver Failure Reversed by Transjugular Intrahepatic Portosystemic Shunt in Patients With Fluid Overload: A Case-Control Study

    by Eduardo Cervantes-Alvarez, Wenyi Gu, Jonathan Byrtus, Carsten Meyer, Markus Treitl, Wulf Euringer, Alexander Gerbes, Joan Clària, Ferran Aguilar, Tilman Sauerbruch, et al.

    INTRODUCTION: Portal hypertension characterizes decompensated cirrhosis and its complications. It may trigger acute-on-chronic liver failure (ACLF), which carries a high mortality. Transjugular intrahepatic portosystemic shunt (TIPS) is the most efficient therapy for most portal hypertension-related complications including fluid overload (FO) defined as refractory or recurrent ascites, hepatorenal syndrome, and/or hydrothorax. However, TIPS for FO in ACLF is questioned. METHODS: In this case-control study, patients from the prospective cohorts CANONIC (n = 1,324) and German TIPS-Registry (n = 724) were screened for cases of FO and matched 1:1 by sex, age, Model for End-Stage Liver Disease (MELD) score, and presence and grade of ACLF. Clinical outcomes, ACLF status, and mortality were assessed. RESULTS: The total population was 118 patients with ACLF of whom 59 received TIPS and 59 did not. The main indication for TIPS was hepatorenal syndrome (61.0%). Patients with ACLF who did not receive TIPS had a higher 28-day cumulative mortality rate (22.0% vs 5.1%, P = 0.009). At 28 days, TIPS insertion in ACLF was associated with a 78% mortality reduction (hazard ratio 0.22 [0.06–0.77]). It further led to improvement of hepatic encephalopathy and the MELD score. In addition, ACLF resolution occurred in 61% of TIPS patients with ACLF. The presence of coagulation and circulatory organ failures, and increased bilirubin, INR, MELD score, and CLIF-C OF were associated with 28-day mortality. The survival benefit of TIPS was no longer observed after 90 days. DISCUSSION: TIPS decreased the 28-day mortality of patients with FO and ACLF. Thus, TIPS should be regarded as a bridging strategy—ideally for liver transplantation.


  • Open Access

    Development and patterns of acute-on-chronic liver failure in patients with cirrhosis and acute kidney injury

    by Susan Fischer, Martin Sebastian McCoy, Marta Fiocco, Annarein Kerbert, Eduardo Cervantes-Alvarez, Jan Hähner, Michael Praktiknjo, Maximilian Joseph Brol, Frank Erhard Uschner, Lena Wolters, et al.


  • Open Access

    Blood-based Vienna 3P/5P risk models accurately predict first hepatic decompensation in compensated advanced chronic liver disease

    by Georg Kramer, Benedikt Simbrunner, Mathias Jachs, Lorenz Balcar, Benedikt Silvester Hofer, Nina Dominik, Lukas Hartl, Michael Schwarz, Georg Semmler, Christian Sebesta, et al.


  • Galectin‐3 is overexpressed in advanced cirrhosis and predicts post‐liver transplant infectious complications

    by Eduardo Cervantes‐Alvarez, Nathaly Limon‐De la Rosa, Mario Vilatoba, Carlos Pérez‐Monter, Sahara Hurtado‐Gomez, Cynthia Martinez‐Cabrera, Josepmaria Argemi, Elisa Alatorre‐Arenas, Susana Yarza‐Regalado, Farid Tejeda‐Dominguez, et al.

    Background & Aims: Patients with advanced cirrhosis often have immune dysfunction and are more susceptible to infections. Galectin‐3 is a β‐galactoside‐binding lectin implicated in inflammation, immune regulation and liver fibrosis. We aim to investigate galectin‐3 expression in advanced cirrhosis and its ability to predict post‐transplant infectious complications.Methods: We collected sera and liver samples from 129 cirrhotic patients at the time of liver transplantation and from an external cohort of 37 patients with alcoholic liver disease including alcoholic hepatitis (AH) at the time of diagnosis. Galectin‐3 was assessed by ELISA, real‐time PCR, immunohistochemistry and RNA‐seq. Receiver operating characteristic curves and Cox proportional‐hazards regression analysis were performed to assess the predictive power of galectin‐3 for disease severity and post‐transplant infections.Results: Increased galectin‐3 levels were found in advanced cirrhosis. Galectin‐3 significantly correlated with disease severity parameters and inflammatory markers. Galectin‐3 had significant discriminating power for compensated and advanced cirrhosis (AUC = 0.78/0.84, circulating/liver galectin‐3; p < .01), and was even higher to discriminate severe AH (AUC = 0.95, p < .0001). Cox Proportional‐hazard model showed that galectin‐3, MELD‐Na and the presence of SIRS predict the development of post‐transplant infectious complications. Patients with circulating galectin‐3 (>16.58 ng/ml) were at 2.19‐fold 95% CI (1.12–4.29) increased risk, but when combined with MELD‐Na > 20.0 and SIRS, the risk to develop post‐transplant infectious complications, increased to 4.60, 95% CI (2.38–8.90).Conclusion: Galectin‐3 is a novel biological marker of active inflammation and disease severity that could be clinically useful alone or in combination with other scores to discriminate advanced cirrhosis and predict post‐transplant infectious complications.


  • Open Access

    Time-Dependent Changes of Laboratory Parameters as Independent Predictors of All-Cause Mortality in COVID-19 Patients

    by Nathaly Limon-De la Rosa, Eduardo Cervantes-Alvarez, Osvely Méndez-Guerrero, Miguel A. Gutierrez-Gallardo, David Kershenobich, Nalu Navarro-Alvarez

    Independent predictors of mortality for COVID-19 patients have been identified upon hospital admission; however, how they behave after hospitalization remains unknown. The aim of this study is to identify clinical and laboratory parameters from admission to discharge or death that distinguish survivors and non-survivors of COVID-19, including those with independent ability to predict mortality. In a cohort of 266 adult patients, clinical and laboratory data were analyzed from admission and throughout hospital stay until discharge or death. Upon admission, non-survivors had significantly increased C reactive protein (CRP), neutrophil count, neutrophil to lymphocyte ratio (NLR) (p < 0.0001, each), ferritin (p < 0.001), and AST (aspartate transaminase) (p = 0.009) compared to survivors. During the hospital stay, deceased patients maintained elevated CRP (21.7 mg/dL [admission] vs. 19.3 [hospitalization], p = 0.060), ferritin, neutrophil count and NLR. Conversely, survivors showed significant reductions in CRP (15.8 mg/dL [admission] vs. 9.3 [hospitalization], p < 0.0001], ferritin, neutrophil count and NLR during hospital stay. Upon admission, elevated CRP, ferritin, and diabetes were independent predictors of mortality, as were persistently high CRP, neutrophilia, and the requirement of invasive mechanical ventilation during hospital stay. Inflammatory and clinical parameters distinguishing survivors from non-survivors upon admission changed significantly during hospital stay. These markers warrant close evaluation to monitor and predict patients’ outcome once hospitalized.


  • Open Access

    Galectin-3 as a potential prognostic biomarker of severe COVID-19 in SARS-CoV-2 infected patients

    by Eduardo Cervantes-Alvarez, Nathaly Limon-De la Rosa, Moises Salgado-De la Mora, Paola Valdez-Sandoval, Mildred Palacios-Jimenez, Fatima Rodriguez-Alvarez, Brenda I. Vera-Maldonado, Eduardo Aguirre-Aguilar, Juan Manuel Escobar-Valderrama, Jorge Alanis-Mendizabal, et al.

    Severe COVID-19 is associated with a systemic hyperinflammatory response leading to acute respiratory distress syndrome (ARDS), multi-organ failure, and death. Galectin-3 is a ß-galactoside binding lectin known to drive neutrophil infiltration and the release of pro-inflammatory cytokines contributing to airway inflammation. Thus, we aimed to investigate the potential of galectin-3 as a biomarker of severe COVID-19 outcomes. We prospectively included 156 patients with RT-PCR confirmed COVID-19. A severe outcome was defined as the requirement of invasive mechanical ventilation (IMV) and/or in-hospital death. A non-severe outcome was defined as discharge without IMV requirement. We used receiver operating characteristic (ROC) and multivariable logistic regression analysis to determine the prognostic ability of serum galectin-3 for a severe outcome. Galectin-3 levels discriminated well between severe and non-severe outcomes and correlated with markers of COVID-19 severity, (CRP, NLR, D-dimer, and neutrophil count). Using a forward-stepwise logistic regression analysis we identified galectin-3 [odds ratio (OR) 3.68 (95% CI 1.47–9.20),p < 0.01] to be an independent predictor of severe outcome. Furthermore, galectin-3 in combination with CRP, albumin and CT pulmonary affection > 50%, had significantly improved ability to predict severe outcomes [AUC 0.85 (95% CI 0.79–0.91,p < 0.0001)]. Based on the evidence presented here, we recommend clinicians measure galectin-3 levels upon admission to facilitate allocation of appropriate resources in a timely manner to COVID-19 patients at highest risk of severe outcome.


  • Increased Hepatic Expression of SARS-CoV-2 Entry Points and Proinflammatory Cytokines in Cirrhosis

    by Nathaly Limon-De La Rosa, Eduardo Cervantes-Alvarez, Nalu Navarro-Alvarez


  • Open Access

    Renal and brain failure predict mortality of patients with acute-on-chronic liver failure admitted to the intensive care unit

    by Osvely Méndez-Guerrero, Daniel A. Calle-Rodas, Eduardo Cervantes-Alvarez, Elisa Alatorre-Arenas, Juanita Pérez-Escobar, Nalu Navarro-Alvarez, Aldo Torre


  • Open Access

    Towards the Study of Liver Failure: Protocol for a 90% Extended Hepatectomy in Mice

    by Maria J. Lizardo Thiebaud, Eduardo Cervantes-Alvarez, Nalu Navarro-Alvarez

    Studies have shown that extended hepatectomy mimics post-hepatectomy liver failure (PHLF) and could also be used to study other small-for-flow syndromes. Extended hepatectomy can be defined as the removal of more than 70% of liver volume. At the molecular level, there seems to be a delayed entrance to the cell cycle, and thus liver dysfunction ensues. Therefore, there is an imperious need to study the mechanisms of such delay to understand how it can be regulated. While the classical 70% hepatectomy model to study liver regeneration has been previously described thoroughly, there are no protocols describing the surgical procedure for a 90% extended hepatectomy (90% EHx). Therefore, we here describe a detailed and reproducible protocol for such model, defining specific aspects that must be considered as well as the most common complications and troubleshooting strategies.


  • Direct or Collateral Liver Damage in SARS-CoV-2–Infected Patients

    by Maria J. Lizardo-Thiebaud, Eduardo Cervantes-Alvarez, Nathaly Limon-De la Rosa, Farid Tejeda-Dominguez, Mildred Palacios-Jimenez, Osvely Méndez-Guerrero, Marco Delaye-Martinez, Fatima Rodriguez-Alvarez, Beatriz Romero-Morales, Wei-Hui Liu, et al.

    Liver injury can result from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with more than one-third of COVID-19 patients exhibiting elevated liver enzymes. Microvesicular steatosis, inflammation, vascular congestion, and thrombosis in the liver have been described in autopsy samples from COVID-19 patients. Several factors, including direct cytopathic effect of the virus, immune-mediated collateral damage, or an exacerbation of preexisting liver disease may contribute to liver pathology in COVID-19. Due to its immunological functions, the liver is an organ likely to participate in the viral response against SARS-CoV-2 and this may predispose it to injury. A better understanding of the mechanism contributing to liver injury is needed to develop and implement early measures to prevent serious liver damage in patients suffering from COVID-19. This review summarizes current reports of SARS-CoV-2 with an emphasis on how direct infection and subsequent severe inflammatory response may contribute to liver injury in patients with and without preexisting liver disease. * Contributed equally to this manuscript. Publication Date: 04 September 2020 (online) © 2020. Thieme. All rights reserved. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.